X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.98 +1.49%

+$0.06 today

Market cap
$304.30M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 0.64M

Average 0.40M

XFOR Total Current Assets

All assets expected to be converted to cash or used up within one year.

X4 Pharmaceuticals, Inc.NASDAQ: XFOR

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets rises 152.9% from a year ago

Total current assets stood at $241.98M at the end of Q1 FY2026, up 152.9% from a year earlier and down 7.5% from the prior quarter. Over 3 fiscal years it compounded at +26.7% a year.

Context

  • Total current assets amounted to 89.5% of total assets at the end of Q1 FY2026, up 15.9 pp from a year earlier.
  • Total current assets increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total current assets keeps rising in the next quarterly balance sheet after a +152.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$241.98M-7.5% QoQ
Last fiscal yearDec 2025
$261.58M+133.2% YoY
Year agoMar 2025
$95.7M+152.9% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+152.9%——
1 year+133.2%——
3-year CAGR+26.7%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
261.58M USD
Year-over-year change
+133.2%
4-year CAGR
+31.3%

Total Current Assets vs competitors

How XFOR compares with its peers on the latest reported figures

  • XFOR's Mar 2026 total current assets of $241.98M is the highest of the 4 companies compared; the peer median is $126.33M.
  • Its year-over-year change of +152.9% is the highest of 4, against a peer median of +8.9%.
  • Total current assets amounts to 89.5% of total assets for XFOR, versus a peer median of 96.1%.
XFOR Competitors Peer median
Total Current Assets for XFOR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XFORX4 Pharmaceuticals, Inc.Mar 2026$241.98M +152.9%+26.7%89.5%
OKUROnKure Therapeutics, Inc.Mar 2026$197.48M +101.2%+64.7%99.4%
KPTIKaryopharm Therapeutics Inc.Mar 2026$126.33M +5.1%-33.5%96.1%
INMBINmune Bio, Inc.Mar 2026$22.82M +8.9%-22.7%88.4%
Peer median (excluding XFOR) $126.33M+8.9%-22.7%96.1%

Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents81.79M121.72M99.22M55.7M217.05M
Short-term Investments0015M46.36M35.95M
Net Receivables747K1.15M562K1.71M573K
Inventory0002.82M4.48M
Other Current Assets5.34M5.81M7.3M5.59M3.53M
Total Current Assets87.88M128.68M122.08M112.18M261.58M
Property, Plant & Equipment (Net)10.22M8.33M6.4M4.84M1.59M
Goodwill17.35M17.35M17.35M17.35M17.35M
Intangible Assets00010M9.25M
Long-term Investments1.32M0000
Tax Assets00000
Other Non-current Assets402K1.23M1.44M2.08M692K
Total Non-current Assets29.3M26.91M25.18M34.27M28.88M
Total Assets117.18M155.59M147.26M146.45M290.46M
Account Payables4.28M7.78M8.95M8.62M5.7M
Short-term Debt1.87M1.32M000
Tax Payables00000
Deferred Revenue0000464K
Other Current Liabilities2.45M6.59M8.2M13.05M4.3M
Total Current Liabilities14.02M22.32M22.86M32.88M25.76M
Long-term Debt33.14M32.3M54.57M75.43M76.29M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0000621K
Other Non-current Liabilities826K23.3M16.12M14.59M1.5M
Total Non-current Liabilities38.74M59.21M73.3M91.42M78.41M
Total Liabilities52.76M81.54M96.16M124.3M104.17M
Common Stock28K122K167K6K91K
Retained Earnings(282.87M)(376.74M)(477.91M)(515.36M)(594.55M)
Accumulated OCI(119K)(119K)(119K)(122K)(109K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity64.41M74.05M51.1M22.15M186.29M
Total Debt39.79M38.42M58.28M78.09M77.29M
Net Debt(42M)(83.3M)(40.94M)22.39M(139.76M)

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.